Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases.
Of 615 patients with impotence of varying etiologies who were followed from 12 to 96 months after the institution of intracavernous self-injection therapy with vasoactive drugs (papaverine alone, papaverine and alpha-blockers, and Ceritine, a new multilevel acting drug) 87% (533 patients) returned for followup visits or were regularly contacted. Of these patients sexual activity was restored in 91%. The dropout rate was 11.25%. The 114 episodes of prolonged erections among 51 patients (4.57%) represented less than 3 per 1,000 of the 34,875 recorded injections. All patients were treated without complications. The percentage of patients suffering from nodules or permanent deformations was 2.8%. There were no cases of intracavernous fibrosis. The percentage of satisfied patients (satisfaction index 7 or greater) was 84.8%. Improvement in spontaneous erections during sexual intercourse was obtained in 65% of the cases: 15% no longer needed self-injections and 50% only used them occasionally while 35% remained entirely dependent.
Virag
R
R
Centre d'Etudes et de Recherches de l'Impuissance, Paris, France.
Shoukry
K
K
Floresco
J
J
Nollet
F
F
Greco
E
E
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D001285:Atropine; D003258:Consumer Behavior; D004176:Dipyridamole; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage* / Q000627:therapeutic use; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000098:blood supply; D010880:Piperidines; D010891:Piribedil; D012039:Regional Blood Flow; D012646:Self Administration; D013997:Time Factors; D015016:Yohimbine
D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D010880:Piperidines; C066901:atropine, dipyridamole, ifenprodil tartrate, papaverine, piribedil, yohimbine drug combination; D015016:Yohimbine; D004176:Dipyridamole; D001285:Atropine; D010208:Papaverine; D010891:Piribedil